Comprehensive analysis of Quant Healthcare Fund - Direct (IDCW) (44198) providing detailed insights into fund performance, portfolio holdings, risk metrics, expense ratios, and investment recommendations.
Quant Money Managers Limited
The investment objective of the scheme is to seek long term capital appreciation by investing in equity/equity related instruments of companies from the healthcare sector. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns.
A comprehensive at-a-glance view of key mutual fund health indicators
Moderate Returns
High Risk
Low Expense Ratio
Equity Focused
Established Team
Average Quality
Showing 1Y NAV history
Performance across different time periods
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Fund shows mixed signals. Consider your investment timeline and risk tolerance.
Review detailed analysis and consider dollar-cost averaging through SIPs.
Historical performance consistency
Recent performance momentum
Market exposure level
Fund management costs
Outperformance vs benchmark
Fund manager experience
Risk-adjusted returns
Assets under management
This fund has underperformed its benchmark by 9.21% over the 3Y period.
See how your money can grow and compare with popular investment options
Disclaimer: Returns are illustrative and based on assumed rates. Mutual fund investments are subject to market risk. Please read scheme documents carefully.
| Company | Industry | % Assets |
|---|---|---|
| TREPS | Debt Others | 11.42% |
| Aster DM Healthcare Ltd | Healthcare | 10.01% |
| Divis Laboratories Ltd | Pharmaceuticals | 9.99% |
| Aster DM Healthcare Ltd | Healthcare | 9.88% |
| TREPS | Debt Others | 9.72% |
| RPG Life Sciences Ltd | Pharmaceuticals | 8.83% |
| RPG Life Sciences Ltd | Pharmaceuticals | 8.78% |
| Sequent Scientific Ltd | Pharmaceuticals | 6.69% |
| Pfizer Ltd | Pharmaceuticals | 6.44% |
| Zydus Wellness Ltd | FMCG | 6.36% |
Compare against Sectoral / Thematic category average
This comparison shows how the fund performs relative to the Sectoral / Thematic category average. Positive values indicate outperformance, while negative values show underperformance.
Compare with similar funds in Sectoral / Thematic category
| Fund Name | NAV | 3M | 6M | 1Y |
|---|---|---|---|---|
| Aditya Birla SL MNC Fund - Direct (G) | ₹1524.25 | 14.28% | 3.38% | 0.21% |
| Aditya Birla SL MNC Fund - (G) | ₹1370.22 | 14.08% | 3.04% | -0.47% |
| Nippon India Banking&Financial Services-Dir(Bonus) | ₹702.57 | 14.57% | 15.30% | 15.12% |
| Nippon India Banking&Financial Services-Dir(G) | ₹702.57 | 14.57% | 15.30% | 15.12% |
| Nippon India Banking&Financial Services (Bonus) | ₹643.19 | 14.33% | 14.82% | 14.17% |
| Nippon India Banking&Financial Services (G) | ₹643.19 | 14.33% | 14.82% | 14.17% |
| Nippon India Pharma Fund - Direct (Bonus) | ₹575.71 | 9.40% | -1.82% | 16.88% |
| Nippon India Pharma Fund - Direct (G) | ₹575.71 | 9.40% | -1.82% | 16.88% |
| Franklin India Technology Fund - Direct (G) | ₹575.22 | 11.95% | -4.25% | 7.83% |
| ICICI Pru FMCG Fund - Direct (G) | ₹523.66 | 5.43% | 1.39% | 0.04% |
A seasoned investment professional with over 2 years of experience in equity research and fund management. Known for consistent performance and a disciplined investment approach focused on quality growth stocks.